Search results for "nonsense mutation"

showing 10 items of 86 documents

Wilms' tumor in patients with 9q22.3 microdeletion syndrome suggests a role for PTCH1 in nephroblastomas

2012

Nephroblastoma (Wilms' tumor; WT) is the most common renal tumor of childhood. To date, several genetic abnormalities predisposing to WT have been identified in rare overgrowth syndromes. Among them, abnormal methylation of the 11p15 region, GPC3 and DIS3L2 mutations, which are responsible for Beckwith-Wiedemann, Simpson-Golabi-Behmel and Perlman syndromes, respectively. However, the underlying cause of WT remains unknown in the majority of cases. We report three unrelated patients who presented with WT in addition to a constitutional 9q22.3 microdeletion and dysmorphic/overgrowth syndrome. The size of the deletions was variable (ie, from 1.7 to 8.9 Mb) but invariably encompassed the PTCH1 …

AdultPatched Receptorsmedicine.medical_specialtyPathologyPTCH1AdolescentNonsense mutationCNVShort ReportReceptors Cell SurfaceBiologymedicine.disease_causeWilms’ tumorWilms TumorFetal MacrosomiaSettore MED/38 - Pediatria Generale E SpecialisticaPregnancyInternal medicineGeneticsmedicineHumansPerlman syndromeChildovergrowthGenetics (clinical)MutationComparative Genomic HybridizationWilms' tumorPTCH1 GeneMicrodeletion syndromeFANCC nephroblastomamedicine.diseaseKidney NeoplasmsPatched-1 ReceptorEndocrinologyPTCH1Settore MED/03 - Genetica MedicaOvergrowth syndromeMutationFemaleChromosome DeletionChromosomes Human Pair 9Comparative genomic hybridization
researchProduct

A novel mutation of the extracellular matrix protein 1 gene (ECM1) in a patient with lipoid proteinosis (Urbach-Wiethe disease) from Sicily

2005

Summary Background  Lipoid proteinosis (LP), also known as Urbach–Wiethe disease, is a rare autosomal recessive disorder characterized by a hoarse voice, warty skin infiltration and scarring. Mutations within the extracellular matrix protein 1 (ECM1) gene cause LP. Objectives  We report the molecular analysis of the ECM1 gene in a Sicilian patient with LP in order to extend the mutation spectrum of this genodermatosis. Methods  We studied a 32-year-old female born from consanguineous parents who was diagnosed at the age of 11 years as having LP. She has a clinical phenotype corresponding to Urbach–Wiethe disease characterized by papules/nodules, indurated plaques and sometimes ulcerated les…

AdultPathologymedicine.medical_specialtySettore MED/09 - Medicina InternaBiopsyMolecular Sequence DataNonsense mutationDermatologyBiologyUrbach–Wiethe diseasemedicine.disease_causePolymerase Chain ReactionFrameshift mutationExtracellular matrix protein 1ExonmedicineHumanseducationSicilyGeneExtracellular Matrix Proteinseducation.field_of_studyMutationBase SequenceGenodermatosisSkin Diseases Geneticmedicine.diseasePedigreeECM1 gene lipoid proteinosis mutationSettore MED/03 - Genetica MedicaCodon NonsenseLipoid Proteinosis of Urbach and WietheSettore MED/26 - NeurologiaFemaleBritish Journal of Dermatology
researchProduct

Identification of D179H, a novel missense GJB2 mutation in a Western Sicily family

2013

The main purpose of this study was to describe a novel missense mutation (p.D179H) found in a Western Sicily family and to examine the genetic and audiologic profiles of all family members by performing a GJB2 and GJB6 mutations analysis and a complete audiologic assessment. The proband was a 3-month-old infant with a congenital profound sensorineural hearing loss; direct sequencing of the GJB2 revealed the presence of a c.35delG mutation in the heterozygous state and a heterozygous G[C transition at nucleotide 535 in trans; this novel mutation, called p.D179H, resulted in an aspartic acid to histidine change at codon 179. It was also evidenced in the heterozygous state in two members of th…

AdultProbandNovel mutationGenotypeHearing Loss SensorineuralDNA Mutational AnalysisNonsense mutationMutation MissenseGenes RecessiveCongenital hearing lossConnexin mutationSeverity of Illness IndexConnexinsmedicineHumansMissense mutationFamilySicilyGeneticsbiologyTransition (genetics)InfantGeneral Medicinemedicine.diseaseGJB2Settore MED/32 - AudiologiaPedigreeNovel mutation Connexin mutation GJB2Sensorineural hearing loss Congenital hearing lossConnexin 26Settore MED/31 - OtorinolaringoiatriaNovel mutation; Connexin mutation; GJB2OtorhinolaryngologyMutation (genetic algorithm)biology.proteinSettore MED/26 - NeurologiaSensorineural hearing lossGJB6European Archives of Oto-Rhino-Laryngology
researchProduct

Translational readthrough of ciliopathy genes BBS2 and ALMS1 restores protein, ciliogenesis and function in patient fibroblasts

2021

Abstract Background Ciliary dysfunction underlies a range of genetic disorders collectively termed ciliopathies, for which there are no treatments available. Bardet-Biedl syndrome (BBS) is characterised by multisystemic involvement, including rod-cone dystrophy and renal abnormalities. Together with Alstrom syndrome (AS), they are known as the ‘obesity ciliopathies’ due to their common phenotype. Nonsense mutations are responsible for approximately 11% and 40% of BBS and AS cases, respectively. Translational readthrough inducing drugs (TRIDs) can restore full-length protein bypassing in-frame premature termination codons, and are a potential therapeutic approach for nonsense-mediated ciliop…

BBS2AdultMaleMedicine (General)AdolescentNonsense mutationAminopyridinesCell Cycle ProteinsCiliopathiesGeneral Biochemistry Genetics and Molecular Biologychemistry.chemical_compoundR5-920AtalurenCiliogenesismedicineHumansReceptors SomatostatinBardet-Biedl SyndromeAlstrom SyndromeCells CulturedOxadiazolesbusiness.industryTumor Suppressor ProteinsTranslational readthroughRProteinsGeneral MedicineFibroblastsmedicine.diseaseNonsense suppressionCiliopathiesAtalurenCiliopathyALMS1chemistryCodon NonsenseAmlexanoxCancer researchMedicineBBS2businessAlström syndromeResearch PaperEBioMedicine
researchProduct

A NOVEL NONSENSE MUTATION IN THE CETP GENE IN ITALIAN HYPERALPHALIPOPROTEINEMIC SUBJECTS

2006

CETPnonsense mutation
researchProduct

Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease.

2013

Fabry disease (FD) is an X-linked hereditary defect of glycosphingolipid storage caused by mutations in the gene encoding the lysosomal hydrolase α-galactosidase A (GLA, α-gal A). To date, over 400 mutations causing amino acid substitutions have been described. Most of these mutations are related to the classical Fabry phenotype. Generally in lysosomal storage disorders a reliable genotype/phenotype correlation is difficult to achieve, especially in FD with its X-linked mode of inheritance. In order to predict the metabolic consequence of a given mutation, we combined in vitro enzyme activity with in vivo biomarker data. Furthermore, we used the pharmacological chaperone (PC) 1-deoxygalacto…

Cancer Research1-Deoxynojirimycinlcsh:QH426-470Nonsense mutationMutantBiologymedicine.disease_causeGeneticsmedicineHumansBiologyMolecular BiologyGenetics (clinical)Ecology Evolution Behavior and SystematicsGeneticsSphingolipidsMutationAlpha-galactosidasePoint mutationmedicine.diseasePhenotypeFabry diseasePharmacological chaperoneProtein Transportlcsh:GeneticsPhenotypeAmino Acid Substitutionalpha-GalactosidaseMutationComputer Sciencebiology.proteinFabry DiseaseMedicineGlycolipidsResearch Articlemedicine.drugPLoS Genetics
researchProduct

Enhancement of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives.

2015

Abstract Premature stop codons are the result of nonsense mutations occurring within the coding sequence of a gene. These mutations lead to the synthesis of a truncated protein and are responsible for several genetic diseases. A potential pharmacological approach to treat these diseases is to promote the translational readthrough of premature stop codons by small molecules aiming to restore the full-length protein. The compound PTC124 (Ataluren) was reported to promote the readthrough of the premature UGA stop codon, although its activity was questioned. The potential interaction of PTC124 with mutated mRNA was recently suggested by molecular dynamics (MD) studies highlighting the importanc…

Cystic FibrosisNonsense mutationPeptide Chain Elongation TranslationalCystic Fibrosis Transmembrane Conductance RegulatorSettore BIO/11 - Biologia MolecolareMolecular Dynamics SimulationCFTR genechemistry.chemical_compoundStructure-Activity RelationshipPlasmidDrug DiscoveryTumor Cells CulturedCoding regionHumansGreen fluorescent proteinGenePharmacologyGeneticsMessenger RNAOxadiazolesNonsense mutationDose-Response Relationship DrugMolecular StructureDrug Discovery3003 Pharmaceutical ScienceOrganic ChemistryTranslational readthroughSettore CHIM/06 - Chimica OrganicaGeneral MedicinePTCs readthroughStop codonAtalurenSettore BIO/18 - GeneticachemistrySettore CHIM/03 - Chimica Generale E InorganicaCodon NonsenseCystic fibrosiMutationFluorinated oxadiazoleHeLa CellsEuropean journal of medicinal chemistry
researchProduct

Toward a Rationale for the PTC124 (Ataluren) Promoted Readthrough of Premature Stop Codons: A Computational Approach and GFP-Reporter Cell-Based Assay

2014

The presence in the mRNA of premature stop codons (PTCs) results in protein truncation responsible for several inherited (genetic) diseases. A well-known example of these diseases is cystic fibrosis (CF), where approximately 10% (worldwide) of patients have nonsense mutations in the CF transmembrane regulator (CFTR) gene. PTC124 (3-(5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl)-benzoic acid), also known as Ataluren, is a small molecule that has been suggested to allow PTC readthrough even though its target has yet to be identified. In the lack of a general consensus about its mechanism of action, we experimentally tested the ability of PTC124 to promote the readthrough of premature termination c…

Duchenne muscular distrophy (DMD)Protein ConformationNonsense mutationBlotting WesternGreen Fluorescent ProteinsPharmaceutical ScienceCystic Fibrosis Transmembrane Conductance RegulatorSettore BIO/11 - Biologia MolecolareBiologyMolecular Dynamics Simulationmedicine.disease_causeReal-Time Polymerase Chain Reactionpremature termination codons (PTC)ArticleGreen fluorescent proteinchemistry.chemical_compoundDrug DiscoverymedicineCoding regionHumansRNA Messengermolecular dynamics (MD)GeneCells CulturedGeneticsnonsense mutation readthroughMessenger RNAMutationOxadiazolesReverse Transcriptase Polymerase Chain Reactiongreen fluorescent protein (GFP)atalurenSettore CHIM/06 - Chimica OrganicaStop codonAtalurenSettore BIO/18 - GeneticachemistryCodon NonsenseSettore CHIM/03 - Chimica Generale E InorganicaMutationCodon TerminatorMutagenesis Site-DirectedMolecular MedicineNucleic Acid Conformationcystic fibrosis (CF)oxadiazoleHeLa Cells
researchProduct

Gene Repair of an Usher Syndrome Causing Mutation by Zinc-Finger Nuclease Mediated Homologous Recombination

2012

PURPOSE. Human Usher syndrome (USH) is the most frequent cause of inherited deaf-blindness. It is clinically and genetically heterogeneous, assigned to three clinical types of which the most severe type is USH1. No effective treatment for the ophthalmic component of USH exists. Gene augmentation is an attractive strategy for hereditary retinal diseases. However, several USH genes, like USH1C, are expressed in various isoforms, hampering gene augmentation. As an alternative treatment strategy, we applied the zinc-finger nuclease (ZFN) technology for targeted gene repair of an USH1C, causing mutation by homologous recombination. METHODS. We designed ZFNs customized for the p.R31X nonsense mut…

Gene isoformNonsense mutationCell Cycle ProteinsBiologyRetinaCell Linechemistry.chemical_compoundHumansDNA Breaks Double-StrandedDNA CleavageHomologous RecombinationGeneAdaptor Proteins Signal TransducingZinc fingerGeneticsTargeted Gene RepairfungiZinc FingersDNAEndonucleasesZinc finger nucleaseCytoskeletal ProteinschemistryCodon NonsenseHomologous recombinationUsher SyndromesDNATargeted Gene RepairInvestigative Opthalmology & Visual Science
researchProduct

A novel nonsense mutation in exon 2 of the factor IX gene resulting in severe haemophilia B

2006

GeneticsCalciphylaxismedicine.diagnostic_testbusiness.industrymedia_common.quotation_subjectNonsense mutationNonsensemedicine.diseaseExonEmergency MedicineInternal MedicineMedicineHaemophilia BbusinessGeneGenetic testingFactor IXmedicine.drugmedia_commonInternal and Emergency Medicine
researchProduct